



Structural Characterization and Extended Substrate Scope Analysis of Two Mg²⁺-Dependent O-Methyltransferases from Bacteria**

Nika Sokolova,^[a] Lili Zhang,^[b] Sadaf Deravi,^[a] Rick Oerlemans,^[b] Matthew R. Groves,^[b] and Kristina Haslinger^{*,[a]}

Oxygen-directed methylation is a ubiquitous tailoring reaction in natural product pathways catalysed by O-methyltransferases (OMTs). Promiscuous OMT biocatalysts are thus a valuable asset in the toolkit for sustainable synthesis and optimization of known bioactive scaffolds for drug development. Here, we characterized the enzymatic properties and substrate scope of two bacterial OMTs from *Desulfotomaculum acetoxidans* and *Streptomyces avermitilis* and determined their crystal structures. Both OMTs methylated a wide range of catechol-like substrates, including flavonoids, coumarins, hydroxybenzoic acids, and

their respective aldehydes, an anthraquinone and an indole. One enzyme also accepted a steroid. The product range included pharmaceutically relevant compounds such as (iso)fraxidin, iso(scopoletin), chrysoeriol, alizarin 1-methyl ether, and 2-methoxyestradiol. Interestingly, certain non-catechol flavonoids and hydroxybenzoic acids were also methylated. This study expands the knowledge on substrate preference and structural diversity of bacterial catechol OMTs and paves the way for their use in (combinatorial) pathway engineering.

Introduction

Methylation is a common modification of all major classes of secondary metabolites and alters their physicochemical properties and biological activity. In particular, oxygen-directed methylation (O-methylation) of natural product scaffolds increases their lipophilicity, introduces steric effects that may affect conformation, and stabilizes reactive intermediates in multistep biosynthetic pathways.^[1,2] Accordingly, this “methyl effect” is widely used in medicinal chemistry to increase membrane permeability, bioavailability, and stability of lead compounds in drug development and modulate target-binding properties.^[2,3]

In nature, methylation of hydroxyl groups is carried out by O-methyltransferases (OMTs) – a diverse family of enzymes relying primarily on S-adenosylmethionine (SAM) as methyl

donor. One subgroup of secondary metabolite methyltransferases known as Class I or catechol OMTs (COMTs) catalyses methylation of phenols bearing vicinal hydroxyl groups (catechols), often with a preference for one of the two positions.^[2] The resulting mono-O-methylated catechol group, the guaiacol, is a recurring motif in many natural products of pharmaceutical and nutraceutical interest, including vanillin, eugenol, capsaicin, and methylated flavonoids. COMTs are also well-studied in animals due to their role in the inactivation of catecholamine neurotransmitters and xenobiotics.^[4] One characteristic of COMTs is their dependence on the binding of a divalent cation, usually Mg²⁺, for full catalytic activity. Metal-independent or Class II OMTs, on the other hand, utilize a catalytic base for deprotonation of the target hydroxyl group and have a broader substrate scope than Class I OMTs.^[5]

While best studied in plants and animals, class I OMTs are also ubiquitous in bacteria. In some cases, they are encoded in secondary metabolite biosynthetic gene clusters (BGCs), where they methylate precursors of complex antibiotic agents such as the L-DOPA building block in saframycin MX1^[4] or 4,5-dihydroxyanthranilic acid in tomaymycin.^[7] The guaiacol group is also present in limazepines^[8] and streptonigrin,^[9] although the OMTs from the corresponding BGCs have not been characterized. The majority of known bacterial COMTs, however, are encoded outside of BGCs, and their cellular targets and physiological functions remain elusive. Several *in vitro* activity studies demonstrate a high tolerance of bacterial COMTs towards non-natural catechol substrates such as catecholamines, phenylpropanoids, and flavonoids.^[10–13]

Heterologously expressed OMTs have already been successfully integrated in engineered pathways towards high-value compounds like ferulic acid,^[14] curcuminoids,^[15] and vanillin,^[16–18] with the latter resulting in the establishment of a commercial

[a] N. Sokolova, S. Deravi, Prof. Dr. K. Haslinger
Department of Chemical and Pharmaceutical Biology
University of Groningen
Antonius Deusinglaan 1, 9731AV Groningen (The Netherlands)
E-mail: k.haslinger@rug.nl

[b] L. Zhang, R. Oerlemans, Prof. Dr. M. R. Groves
XB20 Department of Drug Design
University of Groningen
Antonius Deusinglaan 1, 9731AV Groningen (The Netherlands)

[**] A previous version of this manuscript has been deposited on a preprint server (<https://doi.org/10.1101/2023.01.28.526015>)

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/cbic.202300076>

This article is part of the Special Collection ChemBioTalents2022. Please see our homepage for more articles in the collection.

© 2023 The Authors. ChemBioChem published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

process. Additionally, a number of recent studies have focused on the fine-tuning of COMT regioselectivity,^[12,19] but the substrate scope is mostly confined to plant phenylpropanoids and flavonoids. As O-methylation is one of the most common tailoring reactions in natural product biosynthesis alongside hydroxylation, glycosylation, and prenylation, promiscuous OMTs are a valuable asset in the toolkit for pathway engineering and diversity-oriented combinatorial biosynthesis.^[20] To that end, thorough characterization of the substrate and product scope of candidate enzymes is essential to fully exploit their catalytic potential.

Here, we report heterologous expression and *in vitro* characterization of two promiscuous O-methyltransferases from bacteria. We evaluated the biosynthetic potential of these OMTs on a set of representative natural product scaffolds, demonstrating the successful methylation of several non-canonical substrates and revealing the substrate-dependent nature of OMT regioselectivity. The product scope of the OMTs included several compounds of pharmaceutical and nutraceutical relevance. We furthermore determined high-resolution X-ray crystal structures of the OMTs to reveal potential target sites for tuning regioselectivity or enhancing the catalytic efficiency by enzyme engineering.

Results and Discussion

Biochemical characterization and *in vitro* activity assays

In a previous study,^[14] we used cell-free transcription/translation followed by *in vitro* activity testing to screen a panel of putative O-methyltransferases against several catechol-like compounds. Some of these enzymes catalysed regiospecific methylation of caffeic acid to ferulic acid *in vitro* and in an *Escherichia coli* cell factory. From this set of enzymes, we selected two OMTs for further characterization and substrate scope analysis in this study. Both proteins belong to the PF01596 family, characterized members of which include mammalian COMTs, plant caffeoyl-CoA and flavonoid OMTs, and several secondary metabolite OMTs from bacteria and fungi. The first enzyme, StrAOMT from *Streptomyces avermitilis* (UniProt accession:

Q82B68), was the top-performing enzyme in our screening study^[14] and had previously been shown to methylate several flavonoids *in vitro*.^[10] The second enzyme, DesAOMT from *Desulfuromonas acetoxidans* (UniProt accession: Q1JXV1), is an otherwise uncharacterized protein. DesAOMT struck us as interesting due to its lower molecular weight and a modified catalytic triad “R–N–K” instead of the “K–N–D” conserved in all known Class I plant and bacterial OMTs.^[21]

First, we performed an analysis of the genome neighbourhood^[22] of the OMT-encoding genes and their sequence homologs to check for clues on the natural substrates and functions of these enzymes (Figure S1). We saw that the StrAOMT encoding gene is surrounded, among others, by domains encoding putative lipase, acetyl-CoA acetyltransferase, and cholest-4-en-3-one 26-monooxygenase functionalities, which are indicative of a steroid metabolic pathway, as well as several transporters and a prenyltransferase-like repeat protein in the extended neighbourhood. This motivated us to include a terpene and a steroid derivative in the substrate scope analysis. In a broader phylogenomic analysis, we noticed that the StrAOMT gene neighbourhood is highly conserved in other *Streptomyces* genomes.

The immediate neighbourhood of the DesAOMT gene contains diguanylate cyclase and diguanylate phosphodiesterase domains, which are likely responsible for the synthesis and degradation of a bacterial messenger cyclic di-GMP (Figure S1). We did not find any literature precedent for an association of such genes with methyltransferases, and this combination of genes does not appear to be conserved among sequence homologues of DesAOMT.

Second, we characterized both enzymes biochemically. Following up on our screening study,^[14] we chose to perform the initial assays with the model plant COMT substrate caffeic acid. We cloned the two genes into pET-21b(+) with a C-terminal 6xHis-tag for expression in *E. coli*. We purified the proteins to homogeneity with a two-step protocol comprising nickel-affinity and size-exclusion chromatography (Figure S2). Next, we confirmed that the purified enzymes were capable of methylating caffeic acid under the previously used reaction conditions^[14,23] to the *meta*- and the *para*-methoxy products, ferulic acid (FA) and iso-ferulic acid (IFA), respectively. The differences in the hydrophobicity of FA and IFA, commonly observed with O-methylated regioisomers, allowed for their separation using an HPLC-based method (Figure 1a). We then set out to optimize the reaction conditions. Both enzymes were tolerant to higher reaction temperatures with the maximum catalytic activity at 40 °C and 45 °C for DesAOMT and StrAOMT, respectively (Figure 2b). Since the melting temperature of the enzymes in differential scanning fluorimetry was in the range of 45–55 °C under similar conditions (data not shown), we chose to perform all the following assays at 37 °C to avoid the risk of enzyme instability. We confirmed that both enzymes are dependent on Mg²⁺ for catalytic activity (Figure 2c, d): the addition of Ca²⁺ or ethylenediaminetetraacetic acid (EDTA) fully inhibited both enzymes, whereas we observed weak residual activity in reactions with no additives (“none”). This may be attributed to the presence of residual Mg²⁺ from protein



Kristina Haslinger conducted her PhD research at the Max Planck Institute for Medical Research in Heidelberg, Germany (2014). After a postdoctoral period with Prof. Kris Prather at MIT (USA), she started her independent research group in 2020 as an Assistant Professor at the University of Groningen, The Netherlands. Her research revolves around the analysis and engineering of biosynthetic pathways with the goal to establish sustainable production routes towards pharmaceutically-relevant natural products and their derivatives. Her group pursues *in vitro* biocatalytic approaches as well as fermentative routes with genetically engineered bacteria and filamentous fungi.




Figure 1. Biochemical properties of DesAOMT and StrAOMT with caffeic acid as substrate. Standard reaction conditions (if not stated otherwise): 20 mM Tris-HCl pH 7.5, 20 mM MgCl₂, 100 μM caffeic acid, 200 μM SAM, 1 μM enzyme; 1 h at 37 °C without shaking. a) Chromatogram of the OMT-catalysed reactions compared to the no enzyme control (“ne”) ($\lambda = 310 \text{ nm}$); b) substrate conversions at different reaction temperatures; c-d) substrate conversions with added Mg²⁺, Ca²⁺, EDTA, or no additives (“none”); e-f) substrate conversions at different buffer pH (buffers: NaPi pH 6; HEPES pH 7; Tris-HCl pH 7.5, 8, 8.5; Gly-NaOH pH 9, 10, 11); g-h) substrate conversions in the presence of organic solvents; i-j) Michaelis-Menten kinetics of StrAOMT and DesAOMT. The data are represented as mean \pm standard deviation of three technical replicates. The full statistical report for non-linear regression is shown in Table S1.

purification and storage. Alkaline conditions were preferred by both enzymes with an optimum at pH 8 in Tris-HCl buffer (Figure 1e, f; Figure S3). It is noteworthy that increasing the pH prompted a noticeable shift in regioselectivity of StrAOMT, while maintaining a preference for the *meta*-isomer (ferulic acid). With a decrease in activity, StrAOMT appears to become less regioselective at pH higher than 8. DesAOMT showed lower regioselectivity that remained stable across a wide pH range. With the optimized temperature and buffer conditions (37 °C, Tris-HCl pH 8) and by using a 5-fold excess of SAM, we achieved ~85% conversion of caffeic acid by both enzymes in one hour. Higher conversion rates could be achieved by further increasing the concentration of SAM.

Since several compounds in our intended substrate panel are poorly soluble in water, we sought to explore how tolerant DesAOMT and StrAOMT are to organic solvents. To our surprise, increasing concentrations of dimethylsulfoxide (DMSO) and acetonitrile (ACN) to 20% (v/v) did not significantly affect catalytic activity of the OMTs, while methanol inhibited DesAOMT only at 20% (v/v) (Figure 1g, h). Due to the lack of reports on the solvent tolerance of O-methyltransferases in general, it is not known whether this is a common feature of the COMT family (or its bacterial clade) or is specific for StrAOMT and DesAOMT. Finally, we determined the apparent Michaelis-Menten kinetic parameters at a fixed SAM concentration of 1 mM at 37 °C and pH 7.5. We stopped the reactions




Figure 2. *In vitro* activity and regioselectivity of DesAOMT and StrAOMT with catechol-like compounds. a) Panel of catechol-like substrates highlighting possible O-methylation sites in red and blue; b) HPLC-based identification of reaction products of StrAOMT and DesAOMT exemplified by substrate 6. Solid lines – reaction products, dashed lines – authentic standards of the potential products isofraxidin (triangle) and fraxidin (diamond), ne – “no enzyme” control; detection at $\lambda = 310$ nm; c) and d) conversion of substrates 1–10 into the two possible products depicted as stacked histograms (colour coding according to panel a).

after 5, 10, and 15 min and determined the product concentrations by HPLC to estimate the initial reaction velocities using linear regression (Figure S4). Overall, DesAOMT had a lower apparent K_m for caffeic acid than StrAOMT, while k_{cat}/K_m values were similar for the two enzymes (Figure 1i, j). During this series of experiments, we also noticed strong enzyme inhibition at higher substrate concentrations for both enzymes (8000-fold molar excess of substrate over enzyme). A similar observation was previously reported for the bacterial OMT SafC with caffeic acid and dopamine as substrates,^[6] but the mechanism of this inhibition is not fully understood.

DesAOMT and StrAOMT methylate a variety of catechol-like scaffolds with differing regioselectivity

Next, we set out to assess the performance of DesAOMT and StrAOMT on a range of catechol-like substrates representative of natural product scaffolds, including flavonoids, coumarins, benzoic and resorcylic acids and their respective aldehydes, an anthraquinone, an indole, a terpene and a steroid (Figure 2a, Figure S5). We incubated 0.5 mM of the respective substrate with 5 μ M DesAOMT or StrAOMT for 16 h at 37 °C. We performed the assays at pH 7.5 as some substrates were

unstable in alkaline conditions and added 10–20% DMSO for better solubility of substrates and their methylated products.

Both OMTs exhibited remarkable tolerance towards diverse catechol-like substrates with high conversion rates for substrates 1–10 (Figure 2c, d) and moderate to low conversion rates for substrates 17–24 (Figure S6). For the latter substrates, we detected putative methylated products by LC-MS based on a mass shift of +14 compared to the substrates, however, we did not characterize the products any further because reference compounds were unavailable and the low turnover yields did not warrant in depth structural characterization. Nevertheless, the low level of enzymatic activity observed for these substrates might be an interesting starting point for further investigation.

For substrates 1–10 we confirmed the identity of the products by comparing the HPLC retention times and mass over charge values to those of authentic standards (Figure S7) and thereby assessed the regioselectivity of the enzymes. We found a dependence on the chemical scaffold that differs between the two enzymes. Both were selective for the *meta* hydroxyl of phenolic acids and aldehydes 1–3 and aesculetin 4, but exhibited notable differences when challenged with bulky or highly asymmetric substrates, most notably the coumarins 5 and 6. StrAOMT was selective for the 8-OH of 5 but methylated its 6-methoxy derivative 6 to a mixture of products with only slight preference for the 7-OH to form fraxidin. On the contrary,

DesAOMT was selective for the 7-OH of **5** but produced mostly the 8-O-methylated isofraxidin when challenged with **6** (Figure 2b). Curiously, we observed exclusive conversion of **8** to 3-O-methylated chrysoeriol by both enzymes, which may be attributed to the rigidity and asymmetry of the molecule. Lastly, StrAOMT also converted the steroid **10** to a mixture of 2- and 3-methoxy products. This is consistent with our analysis of the gene neighbourhood of the StrAOMT encoding gene and may indicate that the enzyme has a natural function in steroid metabolism. Overall, our substrate scope analysis with catechol substrates demonstrates the substrate-dependent nature of COMT regioselectivity *in vitro* and highlights the importance of such studies.

DesAOMT and StrAOMT also accept non-catechol substrates

After we characterized the substrate scope of both enzymes for the typical catechol-like substrates, we turned to non-canonical phenolic substrates (Figure S5, 26–31). As expected, many compounds were not methylated, such as those with a single (*m*-coumaric acid) or several *meta*- or *para*-positioned hydroxyl groups (resorcinol, hydroquinone), and phenols with other vicinal substitutions (4-chloro-3-hydroxybenzoic acid, 3-hydroxy-4-methylbenzoic acid). This is probably due to their inability to adopt the proper orientation in the active site and/or coordinate the Mg²⁺ effectively. Similarly, isoferulic acid was not further converted into the dimethylated product.

Unexpectedly, our LC-MS results suggest that StrAOMT and DesAOMT also accept non-catechol flavonoids **11–13** (chrysin, pinocembrin, and naringenin), albeit with low (<10%) conversion rates (Figure 3 and S6). Additionally, StrAOMT can

methylate **14–16** (*p*-orsellinic acid, orcinolaldehyde, and 2,6-dihydroxybenzoic acid) with low conversion rates. The methylated products of flavonoids **11–13** eluted earlier than their substrates, which is atypical since methylation generally increases hydrophobicity of a given compound. Such an elution profile is consistent with literature reports of the rare 5-O-methylated flavonoids.^[21,24] The good agreement of the observed *m/z* values with the theoretical values suggests that **11–13** are methylated to chrysin-5-methylether, alpinetin, and naringenin-5-methylether, respectively (Figure 3b and S6). This assumption is further supported by the fact that the techtochrysin standard – the only other possible methylation product of **11** – does not coelute with the reaction product (Figure 3b). In order to identify the product of the reaction with **14**, we compared its retention time with the readily available authentic standard of its methylester and observed that they do not coelute (Figure 3c). Together with the observed *m/z* value, this suggests that **14** is methylated at either of the two phenolic hydroxyl groups forming a methylether. Based on the inability of DesAOMT and StrAOMT to accept **25–27**, it is plausible that **15** and **16** are also methylated at the *o*-hydroxyl position.

Thus far, methylation of *o*-hydroxybenzoic acids in natural products has only been described for metal-independent enzymes following a different mechanism, as exemplified by calicheamicin orsellinate 2-O-methyltransferase.^[25]

The biosynthesis of 5-methoxyflavonoids remains elusive. Therefore, our findings for these two bacterial COMTs are rather unusual. Mechanistically, however, it is possible that some non-catechol substrates can chelate Mg²⁺ and thus serve as substrates for COMTs, as exemplified by the potent human COMT inhibitors hydroxyquinoline and tropolone.^[4] In addition, the observed 5-O-methylation of flavonoids may be attributed




Figure 3. Non-catechol substrates accepted by StrAOMT (**11–16**) and DesAOMT (**11–13**). a) Panel of non-catechol substrates highlighting putative O-methylation sites in blue; b) and c) elution profiles of StrAOMT-catalysed reactions of **11** and **14** compared to “ne” control and reference compounds of the opposite regioisomers (dashed line); inserts: mass spectra of the putative product peaks (triangle). Detection was performed at $\lambda = 310$ nm. Dimethylated products were not observed.

to enolization of the C-4 carbonyl in a conjugated flav(an)one system, with the resulting hydroxyl group participating in Mg^{2+} coordination.

In order to elucidate the basis of the differing substrate scope and regioselectivities of DesAOMT and StrAOMT, we next turned to the structural characterization of these enzymes.

Crystal structures of StrAOMT and DesAOMT

We determined the crystal structures of apo-DesAOMT at 1.5 Å, apo-StrAOMT at 1.5 Å and SAH-bound StrAOMT at 1.8 Å resolution (Table S2). One asymmetric unit (ASU) of the ligand-free StrAOMT contains two copies of the dimer forming an interface in the substrate-binding site, while a canonical COMT dimer is present in the ASU of the SAH-bound structure (Figure 4a). The crystals of the latter were obtained through co-crystallization of StrAOMT with SAM, Mg^{2+} and caffeic acid, suggesting that the enzymatic reaction proceeded *in situ* and the co-product, SAH, remained bound in the active site. Each StrAOMT monomer in both structures adopts a Rossmann fold, characteristic of SAM-binding proteins, with seven core β -strands surrounded by eight α -helices. The conformation of the apo- and the ligand-bound form of StrAOMT is highly similar,

with an average C α RMSD of 0.451 Å between the monomers. Most notably, SAH binding induces conformational changes in the loop region between $\alpha 2$ and $\alpha 3$ adjacent to SAH (Figure 4b). A search^[26] for structural homologs of the ligand-free structure of StrAOMT identified *Bacillus cereus* BcOMT2 as the top hit (PDB: 3DUW, Z-score 36.6, RMSD 1 Å), closely followed by NkCOMT from *Niastella koreensis* (PDB: 7CVX, Z-score 36.2, RMSD 1.2 Å), TomG from *Streptomyces regensis* (PDB: 5 N5D, Z-score 35.8, RMSD 1.3 Å), a putative OMT from *Klebsiella pneumoniae* (PDB: 3TWF, Z-score 35.6, RMSD 1 Å) and Rv0187 from *Mycobacterium tuberculosis* (PDB: 6JCL, Z-score 34.6, RMSD 1.5 Å) (Table S3). The largest conformational diversity between these structures is observed in the so-called insertion loop between $\beta 5$ and $\alpha 8$ (Figure 4c) – a region implicated in binding Coenzyme A and substrate specificity in plant COMTs. The ASU of DesAOMT contains a single monomer (Figure 4d), but the canonical dimer interface can be identified between two adjacent ASUs. Furthermore, we believe that DesAOMT forms a dimer in solution based on its elution profile during size exclusion chromatography (Figure S2). The otherwise canonical Rossmann fold of DesAOMT is devoid of the N-terminal α -helix, which is present in all known COMT structures determined to date and has been implicated in catalytic activity^[27] and dimerization.^[28] In general, DesAOMT shares little structural




Figure 4. Crystal structures of StrAOMT and DesAOMT. Cartoon representation of a) SAH-bound StrAOMT dimer (holo-, PDB: 8 C9S); b) superimposed structures of apo- (grey, PDB: 8 C9T) and holo-StrAOMT (purple) zoomed in on the $\alpha 2$ - $\alpha 3$ loop adjacent to the ligands; c) comparison of the insertion loops ($\beta 5$ - $\alpha 8$) across DesAOMT (green), StrAOMT (purple), LiOMT (yellow, PDB: 2HNK), SafC (pink, PDB: 5LOG) and rat COMT (grey, PDB: 1H1D); d) apo-DesAOMT monomer (PDB: 8 C9 V); e) superimposed monomer structures of holo-StrAOMT (purple) and DesAOMT (green).

similarity with characterized OMTs, the top hit being LiOMT from *Leptospira interrogans* (PDB: 2HMK, Z-score 26.1, RMSD 1.8 Å), followed by putative OMTs from *Coxiella burnetii* (PDB: 3TR6, Z-score 25.2, RMSD 1.8 Å) and *Mycobacterium tuberculosis* (PDB: 5X7F, Z-score 25.1, RMSD 2 Å), SafC from *Myxococcus xanthus* (PDB: 5LOG, Z-score 25.1, RMSD 1.9 Å) and Rv0187 (PDB: 6JCL, Z-score 24.3, RMSD 1.8 Å), which is also a structural homolog of StrAOMT. Apart from the missing N-terminal helix, a distinct structural feature of DesAOMT is a short insertion loop typical of animal rather than bacterial COMTs (Figure 4c). When comparing with the StrAOMT structures, the RMSD of C α is even higher (2.2 Å) and several conformational differences are apparent (Figure 4e). The most noticeable are in the insertion loop and the β 6- β 7 loop regions.

Active site architecture of StrAOMT and DesAOMT

Both DesAOMT and StrAOMT possess a metal-binding site conserved across all COMTs: D129, D155, N156 in the former and D141, D167, N168 in the latter (Figure S8). In the DesAOMT and holo-StrAOMT structures, we observed electron density in the expected position between these conserved residues and interpreted it as Mg²⁺ (Figure S9). An interpretation as a partially occupied Ca²⁺/Mg²⁺ would also be possible for the DesAOMT structure, since this enzyme was crystallized in a buffer with a mix of divalent metal ions. In holo-StrAOMT, the ion is additionally coordinated by three water molecules, whereas in DesAOMT, one of the waters is replaced by the carbonyl group of N32 (Figure S10). In case of substrate binding, the other two water molecules would likely be replaced by the catechol group of the substrate, as can be seen in other substrate-bound OMT structures.^[27,29] In the holo-StrAOMT structure, we observed additional electron density that we interpreted as 2-pyrrolidone that likely originated from the crystallization solution (Figure S9c). The position of this electron density is not near the catalytic residues and is unlikely to be representative of a substrate- or product-bound state.

Despite numerous attempts, co-crystallization and soaking of StrAOMT with caffeic acid or aesculetin failed to yield substrate-bound crystals. Therefore, we compared the holo-StrAOMT structure to that of its structural homolog NkCOMT, which is complexed with the substrate protocatechuic acid (PDB: 7CVX, chain A) (Figure 5a). The positions of Mg²⁺ and SAH are almost identical in holo-StrAOMT and NkCOMT, as are the residues lining the active sites of the two enzymes. Apart from the Mg²⁺ ion, catalytic activity of known catechol OMTs seems to rely on the absolutely conserved active site triad K–N–D, which is thought to facilitate deprotonation of the aromatic substrate prior to methyl transfer.^[21] K144, N168, and D215 of StrAOMT are aligned with K142, N166, and D213 of NkCOMT, respectively, forming a typical catalytic triad in the active site. The aromatic ring of dihydroxybenzoic acid in NkCOMT is sandwiched between I39 and R169, which are aligned with I41 and R171 in StrAOMT. Additionally, K212 of StrAOMT is aligned with K210 of NkCOMT, which closely approaches the 4-hydroxyl group of the substrate. This double-lysine arrangement is




Figure 5. Active site architectures and substrate-binding pockets of DesAOMT and StrAOMT. a) Superimposed structures of holo-StrAOMT (carbon atoms – purple) and NkCOMT (carbon atoms – grey) complexed with protocatechuic acid (PCA) (PDB: 7CVX); b) superimposed structures of DesAOMT (carbon atoms – green) and SafC (carbon atoms – grey) complexed with dopamine (LDP) (PDB: 5LOG) (other atoms: nitrogen – blue, oxygen – red, sulphur – yellow). Residues within 5 Å of the substrate position are shown. Dashed lines in panel a represent the most important protein-substrate interactions in NkCOMT.

shared by other structural homologs of StrAOMT (PDB: 3DUW, 6JCL, and 3CBG) (Figure S8), although it is not conserved on amino acid sequence level: in structure 3CBG, the 4-hydroxyl binding lysine is residue three located in the N-terminal loop and was shown to be essential for catalytic activity.^[27] In other bacterial COMTs, such as SafC (PDB: 5LOG), the second lysine is not present in the active site.

The closest substrate-bound structural homolog of DesAOMT is SafC complexed with dopamine (PDB: 5LOG). It must be noted that while the unresolved portion of the loop between α 2 and α 3 imposes limitations on the examination of the active site of DesAOMT, several distinct structural features are apparent. As predicted, R132 of DesAOMT is aligned with K145 of SafC, which was shown to be essential for its catalytic activity.^[23] The remaining putative catalytic residues N156 and K186 align with N169 and D212 in SafC. Thus, no major

structural rearrangement takes place in the active site, and the predicted residues are indeed replacing the canonical catalytic triad. Although the sidechain of K186 is currently oriented away from the active site, it is possible that it would rotate closer to the metal ion upon (co-) substrate binding to participate in the catalytic mechanism.

Intrigued by this observation, we inspected the DesAOMT-harboring subcluster of the OMT sequence similarity network generated in our previous study (Figure S11). In this subcluster of 46 sequences mostly from extremophile bacteria, we observed a strict conservation of the R and N of the triad in combination with either K or N. Furthermore, other characteristic features of DesAOMT – namely, the missing N-terminal α -helix and the short insertion loop – were also shared by most sequences (Figure S12). Taken together, these observations hint at a new, possibly more ancient, subgroup of bacterial COMTs with DesAOMT as the first characterized member.

While in plant COMTs the conserved catalytic triad K–N–D was deemed essential for catalysis,^[21] there is no clear consensus on the involvement of the catalytic residues in bacterial COMTs. It is generally assumed that the conserved lysine facilitates deprotonation of a hydroxyl group of the substrate, but results of mutagenesis studies are often inconsistent, ranging from a complete loss of activity^[23] to slight reduction with a change in the regioselectivity profile.^[13] In SynOMT, on the other hand, mutating K3, which is not part of the assumed catalytic triad and is structurally conserved only in a subgroup of bacterial COMTs, completely abolished activity. The unique active site architecture of DesAOMT adds to the long-standing ambiguity surrounding the reaction mechanism of bacterial COMTs, calling for dedicated mechanistic studies similar to those conducted for plant COMTs.

Structural determinants of substrate specificity and regioselectivity

In model COMT structures, the catalytic Mg^{2+} is located at the bottom of a deep groove lined predominantly with hydrophobic residues, which a catechol substrate can penetrate in two possible orientations. Catechols with polar or ionizable side chains are more likely to orient towards the solvent, while substrates with more hydrophobic substituents may favour orientation towards the “hydrophobic wall” of the enzyme; this results in *meta*- or *para*-selective methylation, respectively.^[30] Thus, the regioselectivity of COMT-catalysed methylation is largely dictated by the chemical nature of the substrate, which is also apparent from the regioselectivity patterns of DesAOMT and StrAOMT. For instance, **6** differs from **5** only by an 8-methoxy group, yet StrAOMT exhibits opposite regioselectivities with these two substrates.

Accordingly, engineering efforts to modulate the regioselectivity of COMTs have focused mainly on mutating the residues lining the catechol-binding pocket. A notable example is the Y51R mutation in PFOMT, which alone led to the production of a 1:1 mixture of methylated eriodictyol products (as opposed to the exclusive *meta* methylation of the wild-type enzyme),

while complete transition to *para* selectivity was achieved by an additional N202 W mutation at the opposite site of the catechol pocket.^[19] Depending on the envisioned substrate, several active site residues of StrAOMT could be targeted by site-directed mutagenesis. For dihydroxybenzoic acids and phenylpropanoids, manipulation of the putative carboxyl-binding residues (such as R171) could force the opposite orientation of the substrate for enhanced *para* selectivity, as could the introduction of new positively charged residues instead of G213 or S184.^[19,29] The latter could also be mutated into a bulky residue to probe regioselectivity with larger substrates (flavonoids, coumarins, and anthraquinones). For DesAOMT, however, more mechanistic insight is first needed before rational engineering can be attempted. It would be most intriguing to probe the relevance of the putative catalytic triad one-by-one, or mutating it into the canonical K–N–D triad. Other active site residues such as the putative carboxyl-binding H160 could also be interesting targets of investigation.

Interestingly, despite having highly similar active site architectures, NkCOMT and StrAOMT exhibit differences in the methylation of protocatechuic acid under similar reaction conditions. While the former produced an equal mixture of *meta* and *para* methylated products,^[29] StrAOMT was clearly selective towards the *meta* isomer vanillic acid. This suggests that structural elements distant from the active site may as well influence the regioselectivity of methylation. One such element might be the variable loop connecting the $\beta 5$ strand with the $\alpha 8$ helix. Originally spotted as the main difference between animal and plant COMTs, this “insertion loop” is believed to provide a scaffold for the binding of caffeoyl-CoA in specialized plant enzymes.^[31] A somewhat extended and highly variable loop is also found in the structures of all bacterial COMTs, including StrAOMT. However, its implications in the substrate specificity of bacterial enzymes remain unclear and probably do not involve the binding of CoA.^[6] Curiously, DesAOMT is the first characterized bacterial COMT that possesses a short, animal COMT-like $\beta 5$ - $\alpha 8$ loop. Overall, regioselectivity of DesAOMT and StrAOMT appears to be dictated by a complex interplay between the chemical nature of the substrate, structural elements of the enzyme, and reaction conditions, which agrees with reports for other COMTs.^[12,14,23] The structures of StrAOMT and DesAOMT may be used for deeper investigation of the COMT reaction mechanism and protein engineering efforts to modulate regioselectivity or affinity towards selected substrates. The latter possibility is particularly intriguing with 5-hydroxyflavonoids and 2-hydroxybenzoic acids, which were discovered to be accepted by two bacterial catechol OMTs in this study.

Conclusion

We performed thorough *in vitro* characterization of two promiscuous Class I O-methyltransferases from bacteria and determined their substrate and product scope, methylation regioselectivity and crystal structures. Both enzymes operated in a broad temperature and pH range, exhibited tolerance to organic solvents and methylated a broad range of natural

product scaffolds with differing regioselectivities, which makes them excellent candidates for pathway engineering and combinatorial biosynthesis applications.

Our findings suggest that with optimized reaction conditions or further enzyme and pathway engineering, DesAOMT and StrAOMT could provide a sustainable alternative for the production of several natural products of demonstrated pharmaceutical relevance, such as (iso)fraxidin, (iso)scopoletin, chrysoeriol, alizarin 1-methyl ether, and 2-methoxyestradiol. All of these compounds are currently sourced either from producer plants or through chemical synthesis.

We found that StrAOMT and, to some extent, DesAOMT can methylate *o*-hydroxybenzoic acids and 5-OH flavonoids, which have not been associated with this class of enzymes before. To the best of our knowledge, this is the first report of the enzymatic synthesis of the 5-O-methyl ethers of naringenin, chrysin, and pinocembrin. The latter, better known as alpinetin, is a rare flavonoid with demonstrated potential for the treatment of acute colitis^[32], among other conditions. As the native biosynthetic pathway for alpinetin remains unknown, and no flavonoid-5-OMTs have been described in the literature, StrAOMT is a good candidate for directed evolution efforts towards the improved enzymatic production of this and other 5-O-methylated flavonoids. The structural insights generated in this study may facilitate rational engineering of StrAOMT and DesAOMT towards the improved turnover of non-natural COMT substrates to valuable pharmaceuticals.

Experimental Section

Expression, purification, and storage of DesAOMT and StrAOMT

The genes encoding DesAOMT and StrAOMT were subcloned into pET-21b(+) with a C-terminal 6xHis-tag. Plasmids harbouring the OMT genes were transformed into chemically competent *E. coli* BL21(DE3) and maintained on selective LB agar containing 100 mg/mL ampicillin. A starter culture was inoculated from a single colony (5 mL, LB with ampicillin) and incubated at 37 °C (180 rpm, overnight). The main culture was inoculated from the starter culture (1:100) into auto-induction medium (2% w/v tryptone, 0.5% w/v yeast, 0.5% w/v sodium chloride, 25 mM disodium hydrogen phosphate dihydrate, 25 mM potassium dihydrogen phosphate, 0.6% v/v glycerol, 0.05% w/v glucose, 0.0128% w/v lactose) and incubated at 37 °C (180 rpm, 2 h), after which the temperature was lowered to 18 °C (180 rpm, overnight). All following steps were performed with chilled buffers. The cells were harvested by centrifugation (15 min, 3428 x g) and the pellet was resuspended in 5 volumes of the lysis buffer (buffer A including one EDTA-free protease inhibitor tablet (Roche); buffer A: 50 mM Tris/HCl pH 7.5, 500 mM NaCl, 20 mM imidazole). The cell suspension was lysed by sonication (40% duty cycle, 6 cycles of 30 s ON/30 s OFF) and cleared by centrifugation for 60 min at 25000 xg. The supernatant was loaded onto a HisTrap HP Ni-NTA column (GE Healthcare, USA) connected to an ÄKTA Pure system (Amersham Bioscience, Uppsala, Sweden) and eluted with a linear gradient 0–100% of buffer B (50 mM Tris/HCl pH 7.5, 500 mM NaCl, 500 mM imidazole). Elution fractions corresponding to the protein peak were analysed by SDS PAGE. Fractions with low protein background were pooled and subjected to size-exclusion chromatography on a Superdex 75 pg

column (GE Healthcare, USA) in the storage buffer (DesAOMT: 10 mM Tris/HCl pH 7.4, 20 mM NaCl, 0.2 mM MgCl₂, 5 mM BME; StrAOMT: 10 mM HEPES pH 7, 200 mM NaCl, 0.2 mM MgCl₂, 10 mM DTT, 5% v/v glycerol). The protein concentration was determined by absorbance at 280 nm (NanoDrop, ThermoFisher Scientific, USA) before the purified enzymes were aliquoted and flash-frozen with liquid nitrogen for storage at –80 °C.

Differential scanning fluorimetry (DSF)

For each screening, 0.5 mL of a 1–2 mg/mL protein sample was mixed with 2.5 μL of SYPRO® orange dye (ThermoFisher Scientific, USA) and aliquoted at 5 μL before being mixed with 45 μL of the respective screening buffer. Thermal stability of the protein samples was measured in a CFX96 Dx Real-Time qPCR instrument (Bio-Rad, Hercules, CA, USA); program: 20 °C for 2 min, 20–95 °C over 117 min. Protein melting temperatures (T_m) under the different buffer conditions were determined from the maximum value of the first derivative of the melting curve.

Activity tests

The initial conditions for the *in vitro* OMT reaction were adapted from Siegrist et al.^[23] and included 50 mM HEPES/NaOH pH 7, 20 mM MgCl₂, 1 mM SAM, 0.5 mM substrate (from 80 mM stock in DMSO) and 5 μM enzyme in a total volume of 42 μL. The reactions were started by the addition of the enzyme (or water for the “no OMT” control). The reactions were incubated for 1 h at 30 °C unless stated otherwise, quenched with HClO₄ (final 2% v/v), centrifuged and stored at 4 °C until analysed.

To determine the optimal temperature for the OMT activity, the reactions were incubated in a temperature range of 30–60 °C. All subsequent reactions were incubated at 37 °C. To investigate metal dependence of the OMTs, different cations (Mg²⁺, Ca²⁺, Mn²⁺, Co²⁺, Ni²⁺, Zn²⁺, Cu²⁺) or EDTA were added to the reaction at a concentration of 2 mM alongside a no additive (“none”) control. To study the pH and buffer effects, the reactions were incubated with a 5-fold excess of SAM and 50 mM of the respective buffer (NaPi pH 6; HEPES pH 7; Tris-HCl pH 7.5, 8, 8.5; Glyc-NaOH pH 9, 10, 11). 20 mM Tris-HCl (pH 7.5) was used for subsequent analyses. For solvent tolerance studies, 0–20% (v/v) of DMSO, methanol or acetonitrile was added to the reaction mix right before the addition of the enzyme. For substrate scope studies, the reactions were incubated for 16 h at 37 °C with the addition of 10–20% (v/v) DMSO and a 2-fold excess of SAM.

Steady-state kinetics

Kinetic analyses were performed using 200 nM StrAOMT or 500 nM DesAOMT and 10 to 1000 μM substrate in a reaction mix consisting of 20 mM Tris-HCl pH 7.5, 20 mM MgCl₂ and 1 mM SAM at 37 °C. For the estimation of the initial velocity using linear regression, the reactions were quenched after 5, 10, and 15 min with HClO₄ (final 2% v/v), centrifuged and stored at 4 °C before HPLC analysis. The peak areas were integrated and converted to concentrations in μM based on calibration curves with the authentic standards. The apparent initial velocities of all experiments performed in triplicate were plotted against substrate concentrations using GraphPad Prism 8 and the apparent K_m and k_{cat} constants were determined by non-linear regression with the Michaelis-Menten equation. A full report of the regression statistics is given in Table S1.

Analysis and quantification of OMT reaction products

The supernatants of the quenched OMT reactions were analysed by reversed-phase HPLC (instrument: Shimadzu LC-10AT; autosampler: HiP sampler G1367 A, $T=4^{\circ}\text{C}$, 10 μL injection; flow rate: 1 mL/min; column: Agilent Zorbax Eclipse XDB-C18 80 \AA , 4.6 \times 150 mm, 5 μm , $T=30^{\circ}\text{C}$; detector: SPD-20 A photodiode array detector (PDA), $\lambda=275\text{ nm}$ (SAM/SAH; alizarin, nordihydroguaiaretic acid, 2-hydroxyestradiol and their methylated products) and $\lambda=310\text{ nm}$ (all other substrates and their methylated products); solvents A: water with 0.1% TFA, solvent B: ACN with 0.1% TFA; gradient: 10–28% B over 12.5 min; 28–100% B over 9.5 min; 100–10% B over 2 min; 10% B for 3 min.). For analysing the samples of the steady-state kinetics, a shorter program was used: 10–13% B over 2.5 min; 13–25% B over 1.5 min; 25–35% B over 2 min; 35–65% B over 2 min; 65–100% B over 1 min; 100–10% B over 3 min; 10% B for 3 min. Product peaks were identified by comparing the retention times to authentic standards (where available). The peak areas were integrated and converted to concentrations in μM based on calibration curves with the authentic standards (where available). Regioisomeric excess (RE) of the reaction was calculated using the formula: $(\text{RE} = (\text{c}[\text{meta}]/\text{c}[\text{para}]) / (\text{c}[\text{meta}] + \text{c}[\text{para}]) * 100)$.

The identity of reaction products was furthermore confirmed by HPLC-coupled mass spectrometry (LCMS) with a Waters Acquity Arc UHPLC-MS equipped with a 2998 PDA, and a QDa single quadrupole mass detector. The samples were separated over an XBridge BEH C18 3.5 μm 2.1 \times 50 mm column with a concentration gradient (solvent A: water + 0.1% formic acid, and solvent B: acetonitrile + 0.1% formic acid) at a flow rate of 0.5 mL/min (2 μL injections). The following gradient was used: 5% B for 2 min, 5–90% B over 3 min; 90% B for 2 min; 5% B for 3 min.

Protein crystallization

The sitting-drop vapor diffusion method was applied for crystallization of DesAOMT and StrAOMT at 18°C . Sparse-matrix screening was carried out using the commercial kits JCSG plus, PACT premier, Morpheus, PGA and the MIDAS plus screen (Molecular Dimensions Ltd., UK). Reservoir solution and freshly prepared protein were mixed at a ratio of 1:1 μL . DesAOMT was used at a concentration of 8 mg/ml in 10 mM HEPES pH 7.0, 20 mM NaCl, 0.2 mM MgCl_2 , and 5 mM BME. After 5–6 days, a tetragonal bipyramid-shaped crystal appeared in the well containing reservoir solution of 0.1 M MES/Imidazole pH 6.5, 0.03 M MgCl_2 , 0.03 M CaCl_2 , 20% (v/v) glycerol and 10% (w/v) PEG4000. StrAOMT was concentrated to 13 mg/ml in 10 mM HEPES pH 7, 200 mM NaCl, 0.2 mM MgCl_2 , 10 mM DTT and 5% v/v glycerol. Monoclinic crystals of StrAOMT were obtained in a drop containing reservoir solution of 0.1 M MIB (Malonic acid, Imidazole, Boric acid) pH 6.0 and 25% (w/v) PEG1500.

In order to determine the structure of holo-enzymes, co-crystallization and soaking were attempted with the following ligand combinations: SAH + caffeic acid/aesculetin; SAM + caffeic acid/aesculetin; SAM + ferulic acid. The only combination that yielded well-diffracting crystals was 2.67 mM SAM (from a 32 mM stock containing 5 mM H_2SO_4 and 10% (v/v) EtOH) and 2.5 mM caffeic acid (from a 1 M DMSO stock) incubated with StrAOMT for half an hour at room temperature prior to crystallization. Reservoir solution for the StrAOMT-SAH complex contained 0.2 M ammonium formate, 10% (w/v) polyvinylpyrrolidone, and 20% (w/v) PEG 4000. Crystals were harvested using nylon loops 3–4 days before the diffraction experiments. The crystals were briefly immersed in cryoprotectants made from reservoir solutions supplemented with glycerol (20–30% (v/v)) and flash-cooled in liquid nitrogen.

Diffraction data collection, structure determination and refinement

Diffraction data were collected at beamline P11 at the PETRA III (DESY, Hamburg, Germany) at 100 K. Auto-processing of diffraction data was carried out with XDSAPP^[33], Aimless^[34] in the CCP4 suite^[35] was used for further truncation of the data and analysis of the merging statistics.

The crystal structures were solved through molecular replacement using the MOLREP program^[36]. The apo StrAOMT model was solved using a search model of the monomer of O-methyltransferase from *Bacillus cereus* (PDB entry: 3DUW). Subsequently, the refined model of the apo-StrAOMT monomer served as a search model for the holo-structure of StrAOMT using the DIMPLE pipeline^[37]. Finally, the AlphaFold model (Q1JXV1) was used to solve the DesAOMT structure. All structures were subjected to iterative cycles of refinement and model building using REFMAC5^[38] and Coot^[39]. Automatically determined TLS parameters were used in REFMAC5 for DesAOMT on account of the significant anisotropy detected.

PDB deposition

All three structures were deposited in the PDB under accession codes 8C9V (DesAOMT), 8C9T (apo-StrAOMT), and 8C9S (holo-StrAOMT).

Bioinformatic analyses

Multiple sequence alignments were performed with mafft v7.505^[40] (parameters: $-\text{maxiterate } 1000 - \text{genafpair}$). Gene neighbourhoods of DesAOMT and StrAOMT and their sequence homologs were visualized with the EFI-GNT webtool^[22] using the Single Sequence Blast option and a neighbourhood window size of 20 genes.

Acknowledgements

The authors acknowledge DESY (Hamburg, Germany) for the provision of experimental facilities at PETRA III. NS, SD, and KH are grateful to Dr. Robbert Cool for support with protein purification and Serj Koshian for the initial genome neighbourhood analysis of the OMTs.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Keywords: biocatalysis · methylation · natural products · phenylpropanoids · protein structures

- [1] K. M. Henry, C. A. Townsend, *J. Am. Chem. Soc.* **2005**, *127*, 3724–3733.
[2] A. W. Struck, M. L. Thompson, L. S. Wong, J. Micklefield, *ChemBioChem* **2012**, *13*, 2642–2655.

- [3] K. A. Scott, P. B. Cox, J. T. Njardarson, *J. Med. Chem.* **2022**, *65*, 7044–7072.
- [4] D. A. Learmonth, L. E. Kiss, P. Soares-da-Silva, *Int. Rev. Neurobiol.* **2010**, *95*, 119–162.
- [5] D. K. Liscombe, G. V. Louie, J. P. Noel, *Nat. Prod. Rep.* **2012**, *29*, 1238–1250.
- [6] J. T. Nelson, J. Lee, J. W. Sims, E. W. Schmidt, *Appl. Environ. Microbiol.* **2007**, *73*, 3575–3580.
- [7] W. Li, S. Chou, A. Khullar, B. Gerrataana, *Appl. Environ. Microbiol.* **2009**, *75*, 2958–2963.
- [8] J. Janata, Z. Kamenik, R. Gazak, S. Kadlcik, L. Najmanova, *Nat. Prod. Rep.* **2018**, *35*, 257–289.
- [9] F. Xu, D. Kong, X. He, Z. Zhang, M. Han, X. Xie, P. Wang, H. Cheng, M. Tao, L. Zhang, Z. Deng, S. Lin, *J. Am. Chem. Soc.* **2013**, *135*, 1739–1748.
- [10] Y.-D. Yoon, Y.-H. Park, Y.-S. Yi, Y.-S. Lee, G.-H. Jo, J.-C. Park, J.-H. Ahn, Y.-H. Lim, *J. Microbiol. Biotechnol.* **2010**, *20*, 1359–1366.
- [11] J. H. Cho, Y. Park, J. H. Ahn, Y. Lim, S. Rhee, *J. Mol. Biol.* **2008**, *382*, 987–997.
- [12] Y. Su, H.-P. Li, M. Zhang, X.-W. Ding, J.-H. Xu, Q. Chen, G.-W. Zheng, *ChemCatChem* **2022**, *14*, e202200844.
- [13] S. Lee, J. Kang, J. Kim, *Sci. Rep.* **2019**, *9*, 8059.
- [14] K. Haslinger, T. Hackl, K. L. J. Prather, *Cell Chem. Biol.* **2021**, *28*, 876–886.e4.
- [15] J. L. Rodrigues, D. Gomes, L. R. Rodrigues, *Front. Bioeng. Biotechnol.* **2020**, *8*, 59.
- [16] A. R. Brochado, C. Matos, B. L. Møller, J. Hansen, U. H. Mortensen, K. R. Patil, *Microb. Cell Fact.* **2010**, *9*, 84.
- [17] A. M. Kunjapur, K. L. J. Prather, *ACS Synth. Biol.* **2019**, *8*, 1958–1967.
- [18] A. M. Kunjapur, J. C. Hyun, K. L. J. Prather, *Microb. Cell Fact.* **2016**, *15*, 61.
- [19] M. Dippe, M. D. Davari, B. Weigel, R. Heinke, T. Vogt, L. A. Wessjohann, *ChemCatChem* **2022**, *14*, e202200511.
- [20] X. Wang, C. Wang, L. Duan, L. Zhang, H. Liu, Y. M. Xu, Q. Liu, T. Mao, W. Zhang, M. Chen, M. Lin, A. A. L. Gunatilaka, Y. Xu, I. Molnár, *J. Am. Chem. Soc.* **2019**, *141*, 4355–4364.
- [21] W. Brandt, K. Manke, T. Vogt, *Phytochemistry* **2015**, *113*, 130–139.
- [22] R. Zallot, N. Oberg, J. A. Gerlt, *Biochemistry* **2019**, *58*, 4169–4182.
- [23] J. Siegrist, J. Netzer, S. Mordhorst, L. Karst, S. Gerhardt, O. Einsle, M. Richter, J. N. Anderson, *FEBS Lett.* **2017**, *591*, 312–321.
- [24] K. Somalettha Chandran, J. Humphries, J. Q. D. Goodger, I. E. Woodrow, *Int. J. Mol. Sci.* **2022**, *23*, 3190.
- [25] S. Singh, N. S. Nandurkar, J. S. Thorson, S. Singh, N. S. Nandurkar, J. S. Thorson, *ChemBioChem* **2014**, *15*, 1418–1421.
- [26] L. Holm, *Nucleic Acids Res.* **2022**, *50*, W210–W215.
- [27] J. G. Kopycki, M. T. Stubbs, W. Brandt, M. Hagemann, A. Porzel, J. Schmidt, W. Schliemann, M. H. Zenk, T. Vogt, *J. Biol. Chem.* **2008**, *283*, 20888–20896.
- [28] X. Hou, Y. Wang, Z. Zhou, S. Bao, Y. Lin, W. Gong, *J. Struct. Biol.* **2007**, *159*, 523–528.
- [29] S. H. Lee, B. Kim, K. J. Kim, *J. Agric. Food Chem.* **2021**, *69*, 2531–2538.
- [30] B. J. C. Law, M. R. Bennett, M. L. Thompson, C. Levy, S. A. Shepherd, D. Leys, J. Micklefield, *Angew. Chem. Int. Ed.* **2016**, *55*, 2683–2687; *Angew. Chem.* **2016**, *128*, 2733–2737.
- [31] J. G. Kopycki, D. Rauh, A. A. Chumanevich, P. Neumann, T. Vogt, M. T. Stubbs, *J. Mol. Biol.* **2008**, *378*, 154–164.
- [32] X. He, Z. Wei, J. Wang, J. Kou, W. Liu, Y. Fu, Z. Yang, *Sci. Rep.* **2016**, *6*, 28370.
- [33] M. Krug, M. S. Weiss, U. Heinemann, U. Mueller, *J. Appl. Crystallogr.* **2012**, *45*, 568–572.
- [34] P. R. Evans, G. N. Murshudov, *Acta Crystallogr. D Biol. Crystallogr.* **2013**, *69*, 1204–1214.
- [35] M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. W. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin, K. S. Wilson, *Acta Crystallogr. D Biol. Crystallogr.* **2011**, *67*, 235–242.
- [36] A. Vagin, A. Teplyakov, *J. Appl. Crystallogr.* **1997**, *30*, 1022–1025.
- [37] M. Wojdyr, R. Keegan, G. Winter, A. Ashton, *Acta Crystallogr. Sect. A* **2013**, *69*, 299–299.
- [38] G. N. Murshudov, P. Skubák, A. A. Lebedev, N. S. Pannu, R. A. Steiner, R. A. Nicholls, M. D. Winn, F. Long, A. A. Vagin, *Acta Crystallogr. D Biol. Crystallogr.* **2011**, *67*, 355–367.
- [39] P. Emsley, K. Cowtan, *Acta Crystallogr. D Biol. Crystallogr.* **2004**, *60*, 2126–2132.
- [40] K. Katoh, D. M. Standley, *Mol. Biol. Evol.* **2013**, *30*, 772–780.

Manuscript received: January 31, 2023
Revised manuscript received: March 18, 2023
Accepted manuscript online: March 21, 2023
Version of record online: April 4, 2023